Literature DB >> 16698449

A critical analysis of nonsurgical treatment of Peyronie's disease.

Ekkehard W Hauck1, Thorsten Diemer, Hans U Schmelz, Wolfgang Weidner.   

Abstract

OBJECTIVE: Because the efficacy of nonsurgical therapy of Peyronie's disease is controversial, this review analyses the current status of conservative therapy of Peyronie's disease.
METHOD: A systematic survey on results of studies published as original papers in peer-reviewed journals is provided.
RESULTS: Oral drug therapies include potassium para-aminobenzoate (Potaba), vitamin E, colchicine, tamoxifen, propoleum, acetyl-L-carnitine, and propionyl-L-carnitine. Verapamil, interferon-alpha2a and interferon-alpha2b, collagenase, cortisone, hyaluronidase, and superoxide dismutase are considered intralesional therapies that have had various degrees of success. Other treatments include local gels, iontophoresis, extracorporeal shock wave therapy, and radiation.
CONCLUSION: This review analyses the current status of the conservative therapy of Peyronie's disease, because the efficacy of the nonsurgical therapy is controversial.

Entities:  

Mesh:

Year:  2006        PMID: 16698449     DOI: 10.1016/j.eururo.2006.02.059

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  20 in total

1.  Peyronie's Disease: Nonsurgical Therapy Options.

Authors:  Franklin E Kuehhas; Peter Weibl; Tosev Georgi; Nenad Djakovic; Ralf Herwig
Journal:  Rev Urol       Date:  2011

Review 2.  [Current therapeutic options for Peyronie's disease].

Authors:  A Hauptmann; T Diemer; W Weidner
Journal:  Urologe A       Date:  2013-10       Impact factor: 0.639

3.  [Peyronie's disease: diagnostics and therapy].

Authors:  A Hauptmann; T Diemer; W Weidner
Journal:  Urologe A       Date:  2011-05       Impact factor: 0.639

Review 4.  Nonsurgical treatment options in Peyronie's Disease: 2016 update.

Authors:  Raidh A Talib; Mohammed Abdulkareem Ibrahim; Önder Cangüven
Journal:  Turk J Urol       Date:  2016-12

5.  Intralesional hyaluronic acid: an innovative treatment for Peyronie's disease.

Authors:  Romano Gennaro; Davide Barletta; Gianni Paulis
Journal:  Int Urol Nephrol       Date:  2015-08-11       Impact factor: 2.370

6.  Effects of sildenafil treatment on patients with Peyronie's disease and erectile dysfunction.

Authors:  U Ozturk; S Yesil; H N G Goktug; A Gucuk; C Tuygun; N C Sener; I Nalbant; M A Imamoglu
Journal:  Ir J Med Sci       Date:  2013-11-05       Impact factor: 1.568

7.  Inhibition of histone deacetylase 2 mitigates profibrotic TGF-β1 responses in fibroblasts derived from Peyronie's plaque.

Authors:  Ji-Kan Ryu; Woo-Jean Kim; Min-Ji Choi; Jin-Mi Park; Kang-Moon Song; Mi-Hye Kwon; Nando-Dulal Das; Ki-Dong Kwon; Dulguun Batbold; Guo-Nan Yin; Jun-Kyu Suh
Journal:  Asian J Androl       Date:  2013-06-17       Impact factor: 3.285

8.  Effectiveness of antioxidants (propolis, blueberry, vitamin E) associated with verapamil in the medical management of Peyronie's disease: a study of 151 cases.

Authors:  G Paulis; R D'Ascenzo; P Nupieri; G De Giorgio; G Orsolini; T Brancato; R Alvaro
Journal:  Int J Androl       Date:  2011-09-27

9.  Activin Receptor-Like Kinase 5 Inhibitor Attenuates Fibrosis in Fibroblasts Derived from Peyronie's Plaque.

Authors:  Jin Hyuk Jang; Ji Kan Ryu; Jun Kyu Suh
Journal:  Korean J Urol       Date:  2012-01-25

10.  Effect of SMAD7 gene overexpression on TGF-β1-induced profibrotic responses in fibroblasts derived from Peyronie's plaque.

Authors:  Min Ji Choi; Kang-Moon Song; Jin-Mi Park; Mi-Hye Kwon; Ki-Dong Kwon; Soo-Hwan Park; Dong-Soo Ryu; Ji-Kan Ryu; Jun-Kyu Suh
Journal:  Asian J Androl       Date:  2015 May-Jun       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.